Theravectys
TheraVectys is a French biotech startup specializing in the development of vaccines based on lentiviral vector technology. Their platform focuses on eliciting cellular immune responses, particularly T-Cell responses, to address infectious diseases and cancer. They are pioneering innovative vaccine strategies, including intranasal COVID-19 vaccines, and aim to provide safe, effective, and long-lasting immunization solutions.
Industries
Nr. of Employees
small (1-50)
Products
Lentiviral vector–based intranasal COVID-19 vaccine candidate
A non-integrative lentiviral vector vaccine candidate encoding the SARS-CoV-2 spike protein, formulated for intranasal administration to induce mucosal IgA and systemic cellular and humoral immunity; demonstrated preclinical protection including against variants and protection of the central nervous system in transgenic models.
Pan-coronavirus T-cell vaccine candidate (developmental)
Vaccine constructs designed to target conserved coronavirus T-cell epitopes to provide broader protection against current and future coronavirus variants.
Lentiviral vector–based intranasal COVID-19 vaccine candidate
A non-integrative lentiviral vector vaccine candidate encoding the SARS-CoV-2 spike protein, formulated for intranasal administration to induce mucosal IgA and systemic cellular and humoral immunity; demonstrated preclinical protection including against variants and protection of the central nervous system in transgenic models.
Pan-coronavirus T-cell vaccine candidate (developmental)
Vaccine constructs designed to target conserved coronavirus T-cell epitopes to provide broader protection against current and future coronavirus variants.
Services
Preclinical vaccine development and testing
Design, formulation, and preclinical evaluation of lentiviral vector vaccine candidates in transgenic mouse and hamster models, including assessment of systemic and mucosal immunity and CNS protection.
Viral vector platform optimization and manufacturing support
Upstream production process development including transient transfection workflows, process optimization for yield, and planning for stable packaging cell lines to enable scale-up.
Collaborative translational research with academic institutes
Joint research programs with institutional partners to develop and translate lentiviral vaccine candidates from bench to preclinical proof-of-concept.
Preclinical vaccine development and testing
Design, formulation, and preclinical evaluation of lentiviral vector vaccine candidates in transgenic mouse and hamster models, including assessment of systemic and mucosal immunity and CNS protection.
Viral vector platform optimization and manufacturing support
Upstream production process development including transient transfection workflows, process optimization for yield, and planning for stable packaging cell lines to enable scale-up.
Collaborative translational research with academic institutes
Joint research programs with institutional partners to develop and translate lentiviral vaccine candidates from bench to preclinical proof-of-concept.
Expertise Areas
- Viral vector vaccine development
- T-cell vaccine design and immunology
- Intranasal and mucosal vaccine delivery
- Preclinical model development and translational research
Key Technologies
- Lentiviral vectors (non-integrative)
- DNA-flap genetic element to enhance transduction
- Intranasal delivery platforms
- Transient plasmid transfection production (293T cells)